Vomaris Innovations
1911 E. 5th Street
Tempe
Arizona
85281
United States
Tel: 480-921-4948
Fax: 480-921-0948
Website: http://www.vomaris.com/
About Vomaris Innovations
Vomaris Innovations, Inc., based in Chandler, Arizona, is a regenerative medical device company specializing in the emerging bioelectrical field, generating innovative technologies for the wound care market.
YEAR FOUNDED:
2004
LEADERSHIP:
CEO: Michael Nagel
CMO: Mary Maijer
CFO: Michel Tanguay
PRODUCTS:
9 articles about Vomaris Innovations
-
Study Finds Vomaris Bioelectric Technology Significantly Decreased Biofilm in Burn Patients
3/15/2023
Vomaris Innovations, Inc. announced the publication of results confirming that the company's bioelectric V.Dox™ Technology was effective in preventing and reducing biofilm infection in burn wounds.
-
Vomaris Announces First Patient Enrollment in Study on Effects of Bioelectric Wound Care in Hidradenitis Suppurativa
10/18/2021
Vomaris Innovations, Inc. announces the first patient enrollment in a study using its bioelectric antimicrobial wound care technology following surgical treatment for Hidradenitis Suppurativa (HS).
-
Technology Effective Against Antibiotic-Resistant Pathogen
8/10/2021
Vomaris Innovations, Inc. announced the publication of results demonstrating that the company's bioelectric V.Dox™ Technology is effective in killing antibiotic-resistant Candida albicans pathogens.
-
Vomaris Seeking Expedited FDA Approval for New Virus-Killing Face Mask
4/14/2020
Research shows viruses are killed by exposure to Vomaris Bioelectric V.Dox ™ Technology
-
Vomaris Announces Launch of New Microcurrent-Generating Wound Care Product
3/12/2019
Post-Surgical Dressing Can be 'Built' During Application to Accommodate Virtually Any Incision with One Product Size
-
Study Finds Impact on Endurance Athlete Performance with Electric Field-Generating Compression Garments
3/27/2018
Compression Garments Embedded with Patented V.DoxTM Technology from Vomaris
-
Breakthrough Evidence on Vomaris Bioelectric Technology's Impact on Wound Biofilm Infection
12/5/2017
Vomaris announced today breakthrough results of the first controlled, preclinical in vivo evidence on the anti-biofilm impact of the Company's bioelectric antimicrobial technology.
-
Vomaris' Technology Impacts Biofilm-induced Antibiotic Resistance
4/10/2017
-
Vomaris' JumpStart Product Recognized with Sports Medicine New Technology Award
7/12/2016